All Publications

Publications for all Oxford Principal Investigators within the CAMS Oxford Institute are included here, please use the search functions for publications related to specific Principal Investigators.

Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice.

Salazar V. et al, (2019), Cell Rep, 26, 1585 - 1597.e4

The immune response against flaviviruses.

Slon Campos JL. et al, (2018), Nat Immunol, 19, 1189 - 1198

Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors

López-Camacho C. et al, (2018), Nature Communications, 9

Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Challenges of a Dengue Vaccine.

Screaton G. and Mongkolsapaya J., (2018), Cold Spring Harb Perspect Biol, 10

The immunology of Zika Virus.

Culshaw A. et al, (2018), F1000Research, 7, 203 - 203

Evolution of neurovirulent Zika virus.

Screaton G. and Mongkolsapaya J., (2017), Science (New York, N.Y.), 358, 863 - 864

Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8+ T cell response

Culshaw A. et al, (2017), Nature Immunology, 18, 1228 - 1237

Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection.

Fernandez E. et al, (2017), Nature immunology, 18, 1261 - 1269

The immunopathology of dengue and Zika virus infections.

Culshaw A. et al, (2017), Current opinion in immunology, 48, 1 - 6

Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope.

Rouvinski A. et al, (2017), Nature communications, 8, 15411 - 15411

Antibodies and tuberculosis

Jacobs AJ. et al, (2016), Tuberculosis, 101, 102 - 113

Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus.

Dejnirattisai W. et al, (2016), Nature immunology, 17, 1102 - 1108

Structural basis of potent Zika-dengue virus antibody cross-neutralization.

Barba-Spaeth G. et al, (2016), Nature, 536, 48 - 53

Recent advances in understanding dengue.

Yacoub S. et al, (2016), F1000Res, 5

New insights into the immunopathology and control of dengue virus infection.

Screaton G. et al, (2015), Nat Rev Immunol, 15, 745 - 759

Dengue vaccine development: lessons learnt from asymptomatic infections

Sakuntabhai A. et al, (2015), TROPICAL MEDICINE & INTERNATIONAL HEALTH, 20, 37 - 37

Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.

Dejnirattisai W. et al, (2015), Nat Immunol, 16

Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.

Dejnirattisai W. et al, (2015), Nat Immunol, 16

Recognition determinants of broadly neutralizing human antibodies against dengue viruses.

Rouvinski A. et al, (2015), Nature, 520, 109 - 113

A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.

Dejnirattisai W. et al, (2015), Nat Immunol, 16, 170 - 177

Cookies on this website

All Publications